1 Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
2 Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine 384, 403-416, doi:10.1056/NEJMoa2035389 (2020).
3 Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine 383, 2439-2450, doi:10.1056/NEJMoa2027906 (2020).
4 Health, D. o. Briefing on rescheduling of second doses of the Pfizer/BioNTech Covid-19 vaccine, <https://www.health-ni.gov.uk/news/briefing-rescheduling-second-doses-pfizerbiontech-covid-19-vaccine> (2021).
5 Docherty, A. B. et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 369, m1985, doi:10.1136/bmj.m1985 (2020).
6 Care, D. o. H. a. S. Optimising the COVID-19 vaccination programme for maximum short-term impact. (2021).
7 Ray, D. & Yung, R. Immune senescence, epigenetics and autoimmunity. Clin Immunol 196, 59-63, doi:10.1016/j.clim.2018.04.002 (2018).
8 Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature 586, 583-588, doi:10.1038/s41586-020-2607-z (2020).
9 Libster, R. et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. New England Journal of Medicine, doi:10.1056/NEJMoa2033700 (2021).
10 Madhi, S. A. et al. Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa. medRxiv, 2021.2002.2010.21251247, doi:10.1101/2021.02.10.21251247 (2021).
11 McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630-634, doi:10.1038/s41586-020-03041-6 (2021).
12 Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881-891, doi:10.1016/S0140-6736(21)00432-3 (2021).
13 Bernal, J. L. et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv, 2021.2003.2001.21252652, doi:10.1101/2021.03.01.21252652 (2021).
14 Vasileiou, E. S., Colin & Robertson, Chris & Shi, Ting & Kerr, Steven & Agrawal, Utkarsh & Akbari, Ashley & Bedston, Stuart & Beggs, Jillian & Bradley, Declan & Chuter, Antony & Lusignan, Simon & Docherty, Annemarie & Ford, David & Hobbs, FD & Joy, Mark & Katikireddi, Srinivasa & Marple, James & McCowan, Colin & Sheikh, Aziz. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. (2021).
15 Collier, D. A. et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited neutralizing antibodies. Nature In press, doi:10.1101/2021.01.19.21249840 (2021).
16 Muik, A. et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. bioRxiv, 2021.2001.2018.426984, doi:10.1101/2021.01.18.426984 (2021).
17 Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nature medicine, doi:10.1038/s41591-021-01285-x (2021).
18 Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature, doi:10.1038/s41586-021-03471-w (2021).
19 Anderson, E. J. et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine 383, 2427-2438, doi:10.1056/NEJMoa2028436 (2020).
20 Silva-Cayetano, A. et al. A Booster Dose Enhances Immunogenicity of the COVID-19 Vaccine Candidate ChAdOx1 nCoV-19 in Aged Mice. Med (N Y), doi:10.1016/j.medj.2020.12.006 (2020).
21 Helen Ward et al. REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England. (2021).
22 van den Berg, S. P. H., Warmink, K., Borghans, J. A. M., Knol, M. J. & van Baarle, D. Effect of latent cytomegalovirus infection on the antibody response to influenza vaccination: a systematic review and meta-analysis. Med Microbiol Immunol 208, 305-321, doi:10.1007/s00430-019-00602-z (2019).
23 Peng, Y. et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nature Immunology 21, 1336-1345, doi:10.1038/s41590-020-0782-6 (2020).
24 Zuo, J. et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nature Immunology, doi:10.1038/s41590-021-00902-8 (2021).
25 Ewer, K. J. et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine 27, 270-278, doi:10.1038/s41591-020-01194-5 (2021).
26 Zhu, F. C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 396, 479-488, doi:10.1016/s0140-6736(20)31605-6 (2020).
27 Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594-599, doi:10.1038/s41586-020-2814-7 (2020).
28 Jackson, L. A. et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. New England Journal of Medicine 383, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
29 Akbar, A. N. & Gilroy, D. W. Aging immunity may exacerbate COVID-19. Science 369, 256-257, doi:10.1126/science.abb0762 (2020).
30 Haq, K. & McElhaney, J. E. Immunosenescence: Influenza vaccination and the elderly. Curr Opin Immunol 29, 38-42, doi:10.1016/j.coi.2014.03.008 (2014).
31 Izurieta, H. S. et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 15, 293-300, doi:10.1016/S1473-3099(14)71087-4 (2015).
32 Victora, G. D. & Wilson, P. C. Germinal center selection and the antibody response to influenza. Cell 163, 545-548, doi:10.1016/j.cell.2015.10.004 (2015).
33 Havenar-Daughton, C., Lee, J. H. & Crotty, S. Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem. Immunol Rev 275, 49-61, doi:10.1111/imr.12512 (2017).
34 Gustafson, C. E., Kim, C., Weyand, C. M. & Goronzy, J. J. Influence of immune aging on vaccine responses. J Allergy Clin Immunol 145, 1309-1321, doi:10.1016/j.jaci.2020.03.017 (2020).
35 Bentebibel, S. E. et al. ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination. Sci Rep 6, 26494, doi:10.1038/srep26494 (2016).
36 Lederer, K. et al. SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity 53, 1281-1295 e1285, doi:10.1016/j.immuni.2020.11.009 (2020).
37 Roozendaal, R. et al. SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques. bioRxiv, 2021.2001.2030.428921, doi:10.1101/2021.01.30.428921 (2021).
38 Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature, doi:10.1038/s41586-021-03291-y (2021).
39 Choi, B. et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med, doi:10.1056/NEJMc2031364 (2020).
40 Greinacher, A. et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine, doi:10.1056/NEJMoa2104840 (2021).
41 Kemp, S. et al. Recurrent emergence and transmission of a SARS-CoV-2 Spike deletion H69/V70. bioRxiv, 2020.2012.2014.422555, doi:10.1101/2020.12.14.422555 (2021).
42 Volz, E. et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv, 2020.2012.2030.20249034, doi:10.1101/2020.12.30.20249034 (2021).
43 Cele, S. et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. medRxiv, 2021.2001.2026.21250224, doi:10.1101/2021.01.26.21250224 (2021).
44 Tegally, H. et al. Major new lineages of SARS-CoV-2 emerge and spread in South Africa during lockdown. medRxiv, 2020.2010.2028.20221143, doi:10.1101/2020.10.28.20221143 (2020).
45 Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y. & Leshem, E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet, doi:10.1016/S0140-6736(21)00448-7 (2021).
46 Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. 2020.2006.2008.140871, doi:10.1101/2020.06.08.140871 %J bioRxiv (2020).
47 Mlcochova, P. et al. Combined point of care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G Spike Variant. Cell Rep Med, 100099, doi:10.1016/j.xcrm.2020.100099 (2020).
48 Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nature Structural & Molecular Biology 27, 934-941, doi:10.1038/s41594-020-0478-5 (2020).